2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 323

Impact of Gains in Rheumatoid Arthritis Disease Activity Documentation on Outcomes over Time
Abstract Number: 2566

Impact of Guselkumab Versus Placebo and Adalimumab on Patient Reported Outcomes in Patients with and without Psoriatic Arthritis in a Phase 3 Pivotal Psoriasis Study
Abstract Number: 1696

Impact of Hurricane Maria on a Cohort of Systemic Lupus Erythematosus Patients from Puerto Rico
Abstract Number: 1532

Impact of Immunogenicity on Clinical Efficacy and Administration Related Reaction in TNF Inhibitors: A Pooled-Analysis from Three Biosimilar Studies in Patients with Rheumatoid Arthritis
Abstract Number: 500

Impact of Inflammation and Biologic Treatments on Generation and Progression to Advanced Calcified Coronary Plaques in Rheumatoid Arthritis
Abstract Number: 206

Impact of International Classification of Diseases 10th Revision Codes and Updated Medical Information on an Existing Rheumatoid Arthritis Phenotype Algorithm Using Electronic Medical Data
Abstract Number: 1746

Impact of Interstitial Lung Disease on the Long-Term Survival in 76 Japanese Patients with Microscopic Polyangiitis
Abstract Number: 443

Impact of Intra-Articular Steroid Injection on Bone Marrow Lesions in Osteoarthritis of the Hip: An Assessment Using the Outcome Measures in Rheumatology Hip MRI Inflammation Scoring System
Abstract Number: 1422

Impact of Juvenile Localized Scleroderma on Longitudinal Quality of Life
Abstract Number: 746

Impact of Nephritis on the Outcomes of SLE Patients Hospitalized with Acute Myocardial Infarction; Insights from the National Inpatient Sample Database
Abstract Number: 1547

Impact of Obesity on Drug Survival of Tofacitinib in Patients with Rheumatoid Arthritis: Analysis from the Turkbio Registry
Abstract Number: 665

Impact of Peripheral Manifestations on Patient-Reported Outcomes (PROs) and Treatment in Spondyloarthritis. Data from ASAS-Comospa
Abstract Number: 1390

Impact of Psoriatic Arthritis from the Patient’s Perspective in the Context of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire: An Online Global Survey
Abstract Number: 219

Impact of Rheumatoid Arthritis on Influenza-Related Complications: A Population Based Cohort Study
Abstract Number: 1458

Impact of the Joint Presence of Erosions and ACPA on Rheumatoid Arthritis Disease Activity over Time: Results from the Meteor Registry

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].